EcoDrugPlus

Phosphodiesterase 4d

Ensembl ID : ENSPNYG00000009643
Gene Symbol: PDE4D
3 Cross references
235 Possible Orthologues:

Phosphodiesterase 5a

Ensembl ID : ENSPNYG00000002131
Gene Symbol: PDE5A
4 Cross references
221 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSPNYG00000002806
Gene Symbol: PDE7A
3 Cross references
227 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSPNYG00000013462
Gene Symbol: PDE7B
4 Cross references
189 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSPNYG00000022775
Gene Symbol: PDE9A
1 Cross references
185 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSPNYG00000007028
Gene Symbol: PIK3R1
3 Cross references
202 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSPNYG00000003416
Gene Symbol: PIK3R2
3 Cross references
189 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSPNYG00000017179
Gene Symbol: PIK3R2
3 Cross references
191 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSPNYG00000006124
Gene Symbol: PIK3R3
3 Cross references
171 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSPNYG00000021225
Gene Symbol: PIK3R5
4 Cross references
185 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSPNYG00000016063
Gene Symbol: PIK3R5
3 Cross references
200 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 1 (Alpha)

Ensembl ID : ENSPNYG00000006947
Gene Symbol: PIK3R1
1 Cross references
53 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).